The short answer: almost every FDA announcement a drug company makes answers one of three questions. Does the agency think the drug matters, which is what the designations tell you. What is the legal basis for the approval, which is what the pathways define. And when will it happen, which is what the review clock sets. Once you know which question is being answered, the significance of the news becomes clear.
Here is each one in plain English, including which designations actually mean something and which are routine.
The designations: which ones matter
- Fast Track. Granted for a serious condition with unmet need, at any stage, sometimes on animal data alone. It offers more FDA interaction and eligibility for other programs. It does not mean the agency thinks the drug works. Hundreds are granted a year. Weak signal.
- Breakthrough Therapy. Requires human data showing the drug may be substantially better than existing therapy. This is the strong one. It means the agency looked at real clinical data and was impressed, and practically it usually compresses the timeline by around a year.
- Regenerative Medicine Advanced Therapy (RMAT). Breakthrough’s equivalent for cell and gene therapies. A strong signal that should immediately raise a manufacturing question.
- Priority Review. Shortens the review clock from ten months to six, assigned at filing. It says nothing about the chance of approval, but it tells you the exact date the company must be ready to sell.
- Orphan Drug Designation. For rare diseases. It grants seven years of market exclusivity and tax credits, but no faster review. It is a commercial designation dressed as a regulatory one.
The approval pathways
- Standard NDA (505(b)(1)). The full application for a new drug, backed entirely by the applicant’s own studies. Slowest, most expensive, strongest position.
- The bridge application (505(b)(2)). Relies partly on data the applicant does not own, such as an already approved ingredient. Faster and cheaper, and the route for new formulations and combinations. The most underused pathway.
- The biologic (351(a)). The full application for a biological product, with a far more demanding manufacturing section.
- The biosimilar (351(k)). An abbreviated application for a product highly similar to an approved biologic.
- Accelerated Approval. Based on a surrogate endpoint reasonably likely to predict benefit, with a required confirmatory trial. The most scrutinized pathway today.
The clock
- Standard review of a new molecular entity: about 12 months from submission.
- Priority review of a new molecular entity: about 8 months.
- A Class 2 resubmission after a Complete Response Letter, including anything needing a facility reinspection: 6 months.
A target action date is the most useful piece of commercial intelligence the agency produces, because it is a fixed deadline by which the company must be ready to sell.
Exclusivity and vouchers
Regulatory exclusivity is separate from patents and often more valuable. A new chemical entity gets five years, an orphan drug seven, and a biologic reference product twelve. A priority review voucher, awarded for certain rare pediatric and tropical diseases, is transferable and has historically sold for large sums, which makes a voucher sale a funding event under a different name.
Frequently asked questions
What is the difference between Fast Track and Breakthrough Therapy?
Fast Track is granted for a serious condition with unmet need and can be based on limited data, offering more FDA interaction. Breakthrough Therapy requires preliminary clinical evidence that the drug may be substantially better than existing options, which makes it a much stronger signal and typically compresses the development timeline.
What is the difference between standard and priority review?
Standard review targets a decision about ten months after filing. Priority review targets six months and is granted when a drug may offer a significant improvement. Priority review does not increase the chance of approval, it only shortens the clock.
What does a Complete Response Letter mean?
It means the FDA has declined to approve the application and has explained why. A significant share cite manufacturing or facility issues rather than the drug itself, which means the molecule may work and the problem is fixable with the right manufacturing partner.
What is a priority review voucher worth?
Vouchers are transferable and have historically traded for sums around the range of one hundred million dollars, though the price moves with supply and the underlying programs have faced changing authorization, so current status should be checked.
Get the full cheat sheet
We built a complete reference covering six designations with a signal strength verdict on each, six approval pathways, the review clock, every meeting type, exclusivity, vouchers, and what each milestone means commercially.
